BioInformant

Your Global Leader in Stem Cell Market Research

MENUMENU
  • Blog
    • Interviews
  • News
  • Stem Cells
    • iPS Cells
    • MSCs
    • HSCs
    • Adipose SCs
    • Neural Stem Cells
  • Exosomes
  • CAR-T
  • Cord Blood
  • Shop
    • Products
    • Submit PR
    • Advertise
  • About
    • Testimonials
    • Story
    • Guarantee
    • Contact
  • Home
  • Blog
    • Stem Cells
      • HSCs
      • iPS Cells
      • MSCs
      • Neural Stem Cells
      • Adipose SCs
    • Exosomes
    • Cell Therapy
      • CAR-T
    • Cord Blood
    • Stem Cell News
    • Interviews
  • COVID-19
  • Shop
  • Submit PR
  • Company
    • Advertise
    • Testimonials
    • Story
    • Job Posts
    • Guarantee
    • Privacy Policy
    • Contact
Home » Cynata Announces Japanese Patent Office to Grant Patent for Cymerus™ MSC Technology
Cynata Announces Japanese Patent Office Decision to Grant Patent for Cymerus™ MSC technology

Cynata Announces Japanese Patent Office to Grant Patent for Cymerus™ MSC Technology

May 3, 2016 By Cade Hildreth (CEO) 1 Comment

Cynata TherapeuticsCynata Therapeutics, a stem cell and regenerative medicine company listed on the Australian stock exchange  (ASX: CYP), released major news today that the Japanese Patent Office will grant a patent for its unique Cymerus™ MSC technology.

Discover class-defining bioproduction tools.

To learn more, read the full press release from Cynata Therapeutics, included below with permission Dr. Ross Macdonald, CEO of Cynata Therapeutics.


Cynata Announces Japanese Patent Office Decision to Grant Patent for Cymerus™ MSC Technology

Melbourne, Australia; 2 May 2016 – Australian stem cell and regenerative medicine company, Cynata Therapeutics Limited (ASX: CYP), announced that the Japanese Patent and Trademark Office has issued a Decision to Grant a patent covering certain aspects of its proprietary Cymerus™ mesenchymal stem cell (MSC) manufacturing technology.

bitbio

The patent granted on Japanese Patent Application No. 2013-500186 entitled “Generation of Clonal Mesenchymal Progenitors and Mesenchymal Stem Cell Lines Under Serum-free Conditions” will provide commercial rights in Japan through to 16 March 2031. This patent covers a proprietary method for deriving MSCs from pluripotent stem cells.

Cynata has exclusive rights to this patent and to further patents and patent applications in respect of the Cymerus technology pursuant to a license agreement with the Wisconsin Alumni Research Foundation.

Pluristyx

“Having an issued Japanese patent for our Cymerus technology is a critical step in the development and commercialisation of CYP-001, our first therapeutic MSC product,” said Dr Ross Macdonald, CEO of Cynata. “The issued patent will protect this novel discovery and allow Cynata to further progress its commercial partnering activities in Japan, one of the leading markets for regenerative medicine and stem cells.”

About CYP-001

CYP-001 is Cynata’s lead therapeutic product, an allogeneic, induced pluripotent stem cell (iPSC)-derived MSC. Cynata plans to undertake a Phase 1 clinical trial with CYP-001 in graft-versus-host disease (GvHD) before undertaking development for further disease targets, ideally in collaboration with commercial partners.

About Cynata Therapeutics (ASX: CYP)

Cynata Therapeutics Limited (ASX: CYP) is an Australian stem cell and regenerative medicine company that is developing a therapeutic stem cell platform technology, Cymerus™, originating from the University of Wisconsin-Madison, a world leader in stem cell research. The proprietary Cymerus™ technology addresses a critical shortcoming in existing methods of production of mesenchymal stem cells (MSCs) for therapeutic use, which is the ability to achieve economic manufacture at commercial scale. Cymerus™ does so through the production of a particular type of MSC precursor, called a mesenchymoangioblast (MCA). The Cymerus™ MCA platform provides a source of MSCs that is independent of donor limitations and provides a potential “off-the-shelf” stem cell platform for therapeutic product use, with a pharmaceutical business model and economies of scale. This has the potential to create a new standard in the emergent arena of stem cell therapeutics and provides both a unique differentiator and an important competitive position.

iPSC-derived cardiomyocte therapy

Contacts

Dr Ross Macdonald, Chief Executive Officer: Tel: 0412-119-343; email: ross.macdonald@cynata.com
Dr Stewart Washer, Executive Chairman: Tel: 0418 288212; email: stewart.washer@cynata.com
Kirin Smith, Chief Operations Officer, Investor Contact: Tel: +1 646-863-6519; email: ksmith@pcgadvisory.com
Sean Leous, Chief Communications Officer, Media Contact: Tel: +1 646-863-8998; email: sleous@pcgadvisory.com
Rudi Michelson, Monsoon, Australia Media Contact: Tel: 0411-402-737; email: rudim@monsoon.com.au

Rate this post

Filed Under: iPS Cells, MSCs, Stem Cells Tagged With: Cymerus, cynata therapeutics, mesenchymal stem cells, patent

Related

About Cade Hildreth (CEO)

Cade Hildreth is the Founder of BioInformant.com, the world's largest publisher of stem cell industry news. Cade is a media expert on stem cells, recently interviewed by the Wall Street Journal, Los Angeles Business Journal, Xconomy, and Vogue Magazine. 

Comments

  1. Dr.Gyana Ranjan Padhy M.D.(Medicine) says

    May 3, 2016 at 8:27 pm

    This technology will be adopted for SICKLE CELL DISEASE patients resistant to HYDROXYUREA THERAPY given at our registered research organization THRIVE.This is a beneficial step for them.

    Reply

Tell Us What You Think! Cancel reply

Nanocellect

Marathon Products

Let’s Get Social

  • Facebook
  • Twitter
  • LinkedIn
  • Pinterest
  • Instagram
Menu
  • Blog
  • Stem Cell News
    • Press Releases
  • Stem Cells
    • HSCs
    • iPS Cells
    • MSCs
    • Neural Stem Cells
    • Adipose SCs
  • Exosomes
  • Cell Therapy
    • CAR-T
  • Cord Blood
  • Interviews

Cart

Featured Posts

Cord Blood Market Segmentation

Cord Blood Market Segmentation – Biobanking, HSCT, Cellular Therapy, Genetic Manipulation, & Research Tools

CAR-T Companies

CAR-T Cell Companies Proliferate: List of CAR-T Companies Worldwide

Who discovered stem cells?

Who Discovered Stem Cells? The Answers Revealed

My Tweets

BioInformant's World-Class Clients

  • Submit Press Release
  • Advertise
  • Privacy and Terms

Copyright © 2022 · BIOINFORMANT, Your Global Leader in Stem Cell Market Research

| Email: Info@BioInformant.com | Phone: 703-859-7617 |

800 Corporate Drive, Suite 301, Stafford, VA 22554, United States

Disclaimer: All statements made on this website are NOT expressed as medical claims or advice. They are not intended to diagnose, treat, cure or prevent any disease or condition. If you have a health condition or concern, consult your physician or health care provider.